Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 14/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | MAPK6 | Q16659 | 2/20 | 0.44 |
| ▸ | ITK | Q08881 | 3/20 | 0.43 |
| ▸ | MAP2K7 | O14733 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.42 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16252839 | 0.82 | MAP2K4 (0.51) | MAP2K4MAPK1MAPK6ITKMAP2K7 | |
| SCHEMBL24358756 | 0.79 | PDPK1 (0.58) | — | |
| SCHEMBL15312579 | 0.79 | ITK (0.46) | MAP2K4MAPK1MAPK6ITKMAP2K7 | |
| SCHEMBL5637837 | 0.79 | MAP2K4 (0.44) | MAP2K4DAO | |
| SCHEMBL24358641 | 0.78 | TRPA1 (0.51) | MAP2K4MAPK1MAPK6MAPKAPK2MAPKAPK3 | |
| SCHEMBL9951795 | 0.73 | KDM4E (0.52) | MAP2K4ITKHTR2A | |
| SCHEMBL220002 | 0.73 | PDPK1 (0.60) | MAP2K4MAPK1MAPK6ITKMAP2K7 | |
| SCHEMBL1573990 | 0.73 | MAP2K4 (0.58) | MAP2K4MAPK1MAPK6ITKMAP2K7 | |
| SCHEMBL2595185 | 0.72 | MAP2K4 (0.56) | MAP2K4MAPK1MAPK6ITKMAP2K7 | |
| SCHEMBL8212257 | 0.72 | MAP2K4 (0.56) | MAP2K4MAPK1MAPK6ITKMAP2K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655357-B1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | MERCK SERONO SA (CH) | 2016-06-22 | — | — | EP | disclosed |
| US-9073892-B2 | Indazolyl triazol derivatives | MERCK SERONO S.A. (CH) | 2015-07-07 | — | — | US | disclosed |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | NFATC1, IL5, CD4 | MAP2K4 3270/4885MAPK1 1717/4885MAPK6 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.